Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q2 2022 · 10-Q
Revenue$50.13M$50.13M−36.4% vs Q2 2021 Net Income-$895.00K-$895.00KN/M vs Q2 2021 EPS Diluted-$0.05-$0.05N/M vs Q2 2021 Operating Income$8,662,000−81.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$5,290,000−72.1% Margins · derivedOperating margin17.3%−40.7 pt vs Q2 2021
Net margin-1.8%−40.7 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end